Neurology clinical trials recruiting in Texas

190 recruiting neurology trials match in Texas. Showing 20.

• A Study of Buntanetap in Participants With PDRecruiting

  Phase 2 / Phase 3 · Annovis Bio Inc. · Round Rock, Texas

• A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor FluctuationsRecruiting

  Phase 2 · Appello Pharmaceuticals, Inc. · Round Rock, Texas

• Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)Recruiting

  Phase 3 · Merck Sharp & Dohme LLC · Phoenix, Arizona

• Phosphorylated Tau Levels in Donated BloodRecruiting

  N/A · The University of Texas Health Science Center, Houston · Houston, Texas

• 18F-mFBG Cardiac Uptake With Lewy Body DementiaRecruiting

  Phase 2 · Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) · Houston, Texas

• [18F]PI-2620 Phase 3 Histopathological StudyRecruiting

  Phase 3 · Lantheus Biosciences Ltd. · Dallas, Texas

• A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseaseRecruiting

  Phase 3 · Hoffmann-La Roche · Beaumont, Texas

• A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet SyndromeRecruiting

  Phase 3 · Epygenix · Austin, Texas

• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)Recruiting

  Phase 3 · Bristol-Myers Squibb · El Paso, Texas

• A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)Recruiting

  Phase 3 · Merck Sharp & Dohme LLC · Dallas, Texas

• Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantRecruiting

  Phase 3 · Eidos Therapeutics, a BridgeBio company · Austin, Texas

• Facilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using NeuroimagingRecruiting

  N/A · University of Texas Southwestern Medical Center · Dallas, Texas

• An Online Nurse-Led Purpose-Focused Group Program for Adult Women With Multiple Sclerosis: Effects on Meaning and Quality of LifeRecruiting

  N/A · Texas Woman's University · Denton, Texas

• Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)Recruiting

  Phase 2 · Merck Sharp & Dohme LLC · Austin, Texas

• A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)Recruiting

  Phase 2 · Eli Lilly and Company · Beaumont, Texas

• Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.Recruiting

  Phase 3 · Novartis Pharmaceuticals · Austin, Texas

• A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)Recruiting

  Phase 3 · Merck Sharp & Dohme LLC · Abilene, Texas

• Motor Network PhysiologyRecruiting

  N/A · University of Texas Southwestern Medical Center · Dallas, Texas

• An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)Recruiting

  Phase 2 · Yale University · Aurora, Colorado

• A Study of Orelabrutinib in Patients With Secondary Progressive Multiple SclerosisRecruiting

  Phase 3 · Zenas BioPharma (USA), LLC · San Antonio, Texas

Source: ClinicalTrials.gov. Recruitment status changes often — confirm on each study page.